These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 30552023)

  • 41. Triggering of NF-κB in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy.
    Pfeiffer IA; Hoyer S; Gerer KF; Voll RE; Knippertz I; Gückel E; Schuler G; Schaft N; Dörrie J
    Eur J Immunol; 2014 Nov; 44(11):3413-28. PubMed ID: 25100611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use.
    Kuroki H; Morisaki T; Matsumoto K; Onishi H; Baba E; Tanaka M; Katano M
    Cancer Immunol Immunother; 2003 Sep; 52(9):561-8. PubMed ID: 14627128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
    Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
    Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tick-borne flaviviruses antagonize both IRF-1 and type I IFN signaling to inhibit dendritic cell function.
    Robertson SJ; Lubick KJ; Freedman BA; Carmody AB; Best SM
    J Immunol; 2014 Mar; 192(6):2744-55. PubMed ID: 24532583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
    Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
    J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
    Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X
    Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
    Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
    Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection.
    Fan Z; Huang XL; Kalinski P; Young S; Rinaldo CR
    Clin Vaccine Immunol; 2007 Sep; 14(9):1127-37. PubMed ID: 17634507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.
    Martin K; Müller P; Schreiner J; Prince SS; Lardinois D; Heinzelmann-Schwarz VA; Thommen DS; Zippelius A
    Cancer Immunol Immunother; 2014 Sep; 63(9):925-38. PubMed ID: 24906866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunomodulation in human dendritic cells leads to induction of interferon-gamma production by Leishmania donovani derived KMP-11 antigen via activation of NF-κB in Indian kala-azar patients.
    Chaudhary R; Amit A; Yadav A; Singh A; Kumar V; Singh SK; Narayan S; Rabidas V; Pandey K; Kumar A; Das P; Bimal S
    Biomed Res Int; 2014; 2014():947606. PubMed ID: 24587999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity.
    Wang Y; Song M; Liu M; Zhang G; Zhang X; Li MO; Ma X; Zhang JJ; Huang XY
    Cell Rep; 2021 Apr; 35(1):108948. PubMed ID: 33826900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
    Feili-Hariri M; Falkner DH; Morel PA
    J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
    Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy.
    Kohnepoushi C; Nejati V; Delirezh N; Biparva P
    Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
    Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
    Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.